[The efficacy of the Umex treatment of parkinsonism patients in the initial stage of the disease].

18 patients with early parkinsonism presenting in different clinical forms have undergone 3-month treatment with umex (10 mg/day). The response was evaluated in accordance with unified scale assessing the condition, motor tests, personal and reactive anxiety. Umex brought a significant improvement of motor activity, prolonged the effect of a single dose of DOPA-containing medication, reduced anxiety. Side effects were insignificant.